|Equation||(# individuals tested) x (% individuals tested/vaccinated solely because of the program) x (# QALY increase) x ($ QALY)|
|Explanation||This metric estimates the impact of hepatitis B screening, prevention, and vaccinations leading to improved health, estimated in terms of quality-adjusted life years (QALY).|
Number of individuals vaccinated or tested: Reported by program.
Percentage of participants who are vaccinated solely because of the program:
QALY increase: [0.66]. This is the average impact of screenings computed using summary results reported by Hahné et al (2013).
$ value per QALY: [$50,000]
Benefits are then discounted to present value based on the average age of participation to life expectancy.
|References||Centers for Disease Control and Prevention. (2018). Vaccination Coverage Among Adults in the United States, National Health Interview Survey, 2016. Retrieved from https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/pubs-resources/NHIS2017.html#:~:text=In%202017%2C%20reported%20hepatitis%20B,to%20the%20estimates%20for%202016.|
Hahné, S. J., Veldhuijzen, I. K., Wiessing, L., Lim, T.-A., Salminen, M., & Laar, M. van de. (2013). Infection with hepatitis B and C virus in Europe: a systematic review of prevalence and cost-effectiveness of screening. BMC Infectious Diseases, 13(1).
Nayagam, S., Sicuri, E., Lemoine, M., Easterbrook, P., Conteh, L., Hallett, T. B., & Thursz, M. (2017). Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries. BMC Infectious Diseases, 17(Suppl 1).